Display options
Cite
O'Reilly S, Cant R, Ciechomska M, et al. Interleukin-6: a new therapeutic target in systemic sclerosis?. Clin Transl Immunology. 2013;2(4):e4doi: 10.1038/cti.2013.2.
O'Reilly, S., Cant, R., Ciechomska, M., & van Laar, J. M. (2013). Interleukin-6: a new therapeutic target in systemic sclerosis?. Clinical & translational immunology, 2(4), e4. https://doi.org/10.1038/cti.2013.2
O'Reilly, Steven, et al. "Interleukin-6: a new therapeutic target in systemic sclerosis?." Clinical & translational immunology vol. 2,4 (2013): e4. doi: https://doi.org/10.1038/cti.2013.2
O'Reilly S, Cant R, Ciechomska M, van Laar JM. Interleukin-6: a new therapeutic target in systemic sclerosis?. Clin Transl Immunology. 2013 Apr 12;2(4):e4. doi: 10.1038/cti.2013.2. eCollection 2013 Apr. PMID: 25505952; PMCID: PMC4232056.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Immunology. 2013 Apr 12;2(4):e4. doi: 10.1038/cti.2013.2. eCollection 2013 Apr.

Interleukin-6: a new therapeutic target in systemic sclerosis?.

Clinical & translational immunology

Steven O'Reilly, Rachel Cant, Marzena Ciechomska, Jacob M van Laar

Affiliations

  1. Musculoskeletal Research Group, Institute of Cellular Medicine , Newcastle upon Tyne, UK.

PMID: 25505952 PMCID: PMC4232056 DOI: 10.1038/cti.2013.2

Abstract

Interleukin-6 (IL-6) is a classic pro-inflammatory cytokine critical in mounting an effective immune response. It is secreted by a wide array of cell types; however, its effector cells are more restricted, owing to the fact that very few cells, except lymphocytes and hepatocytes, express the functional membrane IL-6 receptor thus reducing the number of IL-6-responsive cells. Trans-signalling, the shedding of the membrane-bound form of the IL-6 receptor into the local microenvironment, greatly increases the range of cells that can respond. IL-6 has been demonstrated to have a pivotal role in the pathogenesis of rheumatoid arthritis, Castleman's disease and Crohn's disease exemplified by the use of an anti-IL-6 biological therapy. However, IL-6 is also associated with the autoimmune disease systemic sclerosis (SSc) and has been shown to be directly fibrotic. Elevated levels of IL-6 are found in SSc patients and this correlates with skin thickness, suggesting a causal effect. This review focuses on the role of IL-6 in SSc, a chronic autoimmune disease with fibrosis. In particular, we will examine the evidence base of the role of IL-6 in fibrosis in this condition, especially the downstream effector pathways. We will then argue why molecular targeting of IL-6 is a promising therapeutic target in this fibrosing disease.

Keywords: Th17; fibrosis; interleukin-6; interleukin-6 signalling; systemic sclerosis

References

  1. J Dermatol Sci. 2001 Oct;27(2):140-6 - PubMed
  2. Am J Pathol. 2012 Jan;180(1):165-76 - PubMed
  3. J Biol Chem. 2012 Jan 20;287(4):2666-77 - PubMed
  4. J Appl Physiol (1985). 2011 Jun;110(6):1549-54 - PubMed
  5. Blood. 1993 Aug 15;82(4):1120-6 - PubMed
  6. J Immunol. 2007 Oct 1;179(7):4313-7 - PubMed
  7. Science. 1992 Mar 13;255(5050):1434-7 - PubMed
  8. Blood. 2005 May 1;105(9):3512-20 - PubMed
  9. Rheumatol Int. 2011 Jan;31(1):127-31 - PubMed
  10. J Biol Chem. 2002 May 10;277(19):16879-87 - PubMed
  11. Nature. 2006 May 11;441(7090):235-8 - PubMed
  12. Lancet. 2008 Mar 22;371(9617):987-97 - PubMed
  13. J Exp Med. 1999 Feb 1;189(3):599-604 - PubMed
  14. Annu Rev Immunol. 1989;7:145-73 - PubMed
  15. J Rheumatol. 2012 Dec;39(12):2294-302 - PubMed
  16. EMBO Mol Med. 2012 Sep;4(9):939-51 - PubMed
  17. Science. 1994 Jan 7;263(5143):92-5 - PubMed
  18. J Clin Invest. 1999 May;103(9):1253-60 - PubMed
  19. Eur J Immunol. 1994 Aug;24(8):1945-8 - PubMed
  20. Arthritis Rheum. 2012 Sep;64(9):3006-15 - PubMed
  21. J Exp Med. 1998 Feb 16;187(4):461-8 - PubMed
  22. Eur J Immunol. 1993 Feb;23(2):473-80 - PubMed
  23. Blood. 2007 Sep 15;110(6):1748-55 - PubMed
  24. J Rheumatol. 2012 Jun;39(6):1120-4 - PubMed
  25. Ann Rheum Dis. 2012 Jul;71(7):1227-34 - PubMed
  26. J Immunol. 1982 Apr;128(4):1903-8 - PubMed
  27. Cytokine Growth Factor Rev. 2002 Aug-Oct;13(4-5):357-68 - PubMed
  28. Arthritis Rheum. 1992 Jan;35(1):67-72 - PubMed
  29. PLoS One. 2009 Jun 22;4(6):e5981 - PubMed
  30. Rheumatology (Oxford). 2008 Oct;47 Suppl 5:v14-5 - PubMed
  31. Cytokine Growth Factor Rev. 2012 Jun;23(3):99-107 - PubMed
  32. J Immunol. 1995 Dec 1;155(11):5198-205 - PubMed
  33. J Dermatol. 2010 Sep;37(9):801-6 - PubMed
  34. J Biol Chem. 1998 May 29;273(22):13625-9 - PubMed
  35. Arthritis Rheum. 1977 May;20(4):975-84 - PubMed
  36. Int J Immunopathol Pharmacol. 2006 Jul-Sep;19(3):471-87 - PubMed
  37. Arthritis Rheum. 2013 Feb;65(2):481-91 - PubMed
  38. Eur J Biochem. 2000 May;267(9):2624-31 - PubMed
  39. Arthritis Rheum. 1984 Jun;27(6):645-53 - PubMed
  40. J Biol Chem. 2003 Oct 3;278(40):38829-39 - PubMed
  41. Ann Rheum Dis. 2012 Jul;71(7):1235-42 - PubMed
  42. Rheumatology (Oxford). 1999 Jul;38(7):612-7 - PubMed
  43. Am J Respir Cell Mol Biol. 2008 May;38(5):566-71 - PubMed
  44. Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85 - PubMed
  45. J Immunol. 2010 Jun 15;184(12):7219-28 - PubMed
  46. Infect Immun. 1996 Sep;64(9):3646-51 - PubMed
  47. J Immunol. 1981 Aug;127(2):412-6 - PubMed
  48. Clin Immunol. 2011 Jun;139(3):249-57 - PubMed
  49. Rheumatology (Oxford). 2010 Dec;49(12 ):2408-12 - PubMed
  50. Hypertension. 2010 Aug;56(2):225-31 - PubMed
  51. J Biol Chem. 2001 Jun 29;276(26):24414-21 - PubMed
  52. J Immunol. 1998 Dec 15;161(12):6480-6 - PubMed
  53. Rheumatology (Oxford). 2012 Sep;51(9):1540-9 - PubMed
  54. Blood. 2000 Jan 1;95(1):56-61 - PubMed
  55. J Clin Invest. 2011 Sep;121(9):3375-83 - PubMed
  56. Exp Dermatol. 2010 Jan;19(1):38-43 - PubMed
  57. PLoS One. 2012;7(5):e35144 - PubMed

Publication Types